首页 文献索引 SCI期刊 AI助手
期刊目录筛选

期刊名:American society of clinical oncology educational book / asco. american society of clinical oncolog

缩写:

ISSN:1548-8756

e-ISSN:

IF/分区:0.0/

文章目录 更多期刊信息

共收录本刊相关文章索引1256条
Clinical Trial Case Reports Meta-Analysis RCT Review Systematic Review
Classical Article Case Reports Clinical Study Clinical Trial Clinical Trial Protocol Comment Comparative Study Editorial Guideline Letter Meta-Analysis Multicenter Study Observational Study Randomized Controlled Trial Review Systematic Review
Anna Maria Frustaci,Alessandra Tedeschi,Alexander F Vom Stein et al. Anna Maria Frustaci et al.
The rapid development of novel agents and combinations in chronic lymphocytic leukemia/small lymphocytic lymphoma has led to multiple options for frontline therapy and relapse, including continuous therapy and fixed duration regimens. The c...
Shalini Fernando,Van Morris,James Yu et al. Shalini Fernando et al.
Squamous cell carcinoma of the anal canal (SCAC) is a rare, human papillomavirus-driven malignancy with a rising global incidence and an increasingly dynamic therapeutic landscape. This review summarizes recent advances and current evidence...
Lisa Eidenschink Brodersen,Alexandra E Kovach,Jan Zuna Lisa Eidenschink Brodersen
Measurable/minimal residual disease (MRD) monitoring is an essential component of modern treatment protocols for ALL and AML. Early response to therapy, as measured by MRD levels at defined time points during treatment, serves as an importa...
Nazik Hammad,Omar Abdihamid,Moawia Mohammed Ali Elhassan et al. Nazik Hammad et al.
Cancer care in conflict-affected settings represents a growing yet underrecognized global health crisis, disproportionately affecting populations in low- and middle-income countries, particularly in Africa. With over 130 million people forc...
Eitan Amir,Tyler Kristoff,Catherine Blaha et al. Eitan Amir et al.
Treating patients with early-stage hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer is increasingly complex, driven by a growing array of therapeutic options, heterogeneous clinical benefit across p...
Cristiane Bergerot,Laura V M Baum,Ih-Jane Yang et al. Cristiane Bergerot et al.
Cancer diagnosed before age 50 years, commonly referred to as early-onset or young-onset cancer, is an increasingly recognized global public health challenge, with rising incidence across multiple tumor types, including colorectal, breast, ...
Gareth J Morgan,Dennis D Lee,Nisha S Joseph et al. Gareth J Morgan et al.
Despite therapeutic progress, there has been little improvement in the outcome of the 15%-25% of newly diagnosed high-risk multiple myeloma (HRMM), which is characterized by early treatment resistance and very poor survival. HRMM is a subst...
Yin Ting Cheung,Mu-Hsing Ho,Joanna Fardell et al. Yin Ting Cheung et al.
Cancer-related cognitive impairment (CRCI) is common and multifactorial in nature with the cancer itself, various treatment modalities, as well as socioenvironmental, biobehavioral, and lifestyle factors all potentially contributing to cogn...
Naghib Bogere,David Mwiine,Judith Asasira et al. Naghib Bogere et al.
Background: In many low- and middle-income countries, expanding access to cancer services has been a major priority. Yet, patient outcomes increasingly depend not only on whether services exist but on how care is organize...
Arjun Ravishankar,Ganesan Ramamoorthi,Tobias Weiss et al. Arjun Ravishankar et al.
Metastasis is the main cause of cancer death and is driven by the systemic formation of premetastatic niches and immune sanctuaries that protect disseminated cancer cells (DCCs) from immune surveillance and therapy. This review explores the...